Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.

Shinnosuke TakemotoYoichi NakamuraHiroshi GyoutokuHiroaki SenjuDaiki OgawaraTakaya Ikeda Hiroyuki YamaguchiTakeshi KitazakiHirofumi NakanoKatsumi NakatomiShinya TomariShuntaro SatoSeiji NagashimaMinoru FukudaHiroshi Mukae

Published in: Thoracic cancer (2019)

The triplet combination might be effective for patients with advanced, untreated NSCLC overexpressing ERCC1. ERCC1 messenger RNA levels may be a predictive factor for response to platinum-containing regimens.

Keyphrases

dna repair
small cell lung cancer
advanced non small cell lung cancer
energy transfer
single cell
dna damage
cell therapy
nucleic acid
brain metastases
open label
stem cells
clinical trial
oxidative stress
quantum dots
placebo controlled